TherapeuticsMD, Inc.
TherapeuticsMD, Inc. (TXMD) is a small-cap specialty pharmaceutical company focused on women’s healthcare. Investors should know it operates in a high-risk, research-driven segment where companies aim to develop, licence and commercialise therapies for specific patient groups. With a market cap of roughly $13.5m, TXMD is highly exposed to liquidity, clinical, regulatory and commercial execution risks; its share price may be volatile and dilution through additional financing is a realistic possibility. Potential upside could come from successful product launches, partnerships or favourable regulatory outcomes, but outcomes are uncertain. This summary is general educational information and not personal investment advice — consider suitability, your risk tolerance and consult a qualified adviser before acting. Past performance is not indicative of future returns and values can fall as well as rise.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying TherapeuticsMD's stock with a target price of $5, indicating good growth potential.
Financial Health
TherapeuticsMD, Inc. has modest revenue and cash flow, but its financial outlook is uncertain.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring TXMD
Navigating Pharma Price Controls
President Trump's ultimatum to major pharmaceutical firms to lower drug prices creates significant market uncertainty for brand-name drug makers. This situation could benefit companies that thrive on reducing healthcare costs, such as generic drug manufacturers and prescription discount platforms.
Published: August 4, 2025
Explore BasketNew Opportunities in Endometriosis Treatment
This carefully selected group of biopharmaceutical stocks represents companies that could benefit from Organon's recent discontinuation of its endometriosis drug. Our analysts have identified these firms as potential leaders in addressing the significant unmet needs in women's health.
Published: July 3, 2025
Explore BasketDigital Therapeutics & Prescription Apps
Software is becoming the new medicine. These carefully selected companies are developing FDA-cleared applications that treat everything from mental health to diabetes. With growing insurance reimbursement and massive scalability, these digital treatments represent healthcare's next frontier.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Small-cap volatility
Market cap underlines high price swings and limited liquidity; this can mean big gains or losses and possible share dilution.
Product development focus
Progress in clinical or regulatory milestones can materially affect value, though many programmes face setbacks or delays.
Commercial and partners
Partnerships or licensing can expand reach and revenue, but commercial execution and market uptake remain uncertain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
Amgen Inc.
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
ADMA BIOLOGICS INC
Develops products to treat immune deficiencies and chronic diseases.
